We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.80 | 8.24% | 36.80 | 36.60 | 37.30 | 37.30 | 35.00 | 35.00 | 753,383 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -18.81 | 109.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
08/3/2023 22:15 | The Netherlands, wasn't that where Blue Diamond 'came and went'? | glavey | |
08/3/2023 21:31 | Hark at LiarBO accusing someone of copy/pasting! Hahahahahahaha! | petroc | |
08/3/2023 21:30 | The multi-ID stock basher (aka LiamBooth, Leveraged, Citygirl, sbgae, LBO8 et al) is making contradictory claims to the results found in two clinical tests and a home use trial. The vast majority of users confirmed that Eroxon works. LiarBO can't show a single piece of evidence that shows otherwise, which is why he has to use spurious and unrelated links in an attempt to tar Eroxon. | petroc | |
08/3/2023 17:50 | Hark at LiarBO accusing someone of copy/pasting! Hahahahahahaha! | petroc | |
08/3/2023 16:48 | All Futura have done with MED3000 is open the door for Reckitt to sell similar lubricants/arousal gels as medical device placebo treatments for ED. And report Med3000 to the ASA, FTC etc for being misleading if it doesn't inform consumers that MED3000 itself has no proven effect in ED beyond a placebo. As it has no proven efficacy in an adequate placebo controlled study or even against any standard cooling lubricant/arousal gels in an ED study.https://neo.li | lbo | |
08/3/2023 14:15 | BTW, for anyone interested in proper chat about Eroxon, head on over to LSE. They're currently discussing the availability of Eroxon in Europe. No negativity, no back biting, and most importantly, no LiarBO bashing the stock with lies and misinformation! LSE wisely took the decision to ban the lying manipulator over a year ago. | petroc | |
08/3/2023 14:02 | The HCP website that was advertised by Petroc says 'when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important difference' And the HCP Brochure on the same website references the study 'Minimal clinically Important Difference Rosen et al 2011'But its now clear from that exact study that the MCID criteria were estimated based on regular adequately controlled and blinded oral ED studies.The Rosen study also clearly states in its limitations the results have not been replicated in 'non pharmacologic studies'So they are not internationally accepted criteria for 'non pharmacologi studies'or medical device gels which are known to have much higher placebo effect then oral pharmacologic placebos. In one study it was 3 times higher.So now its been shown the MCID is inappropriately being used in HCP marketing to make a indirect cross comparison to non regular inadequately blinded medical device gel studies.https://pubm | lbo | |
08/3/2023 13:57 | As usual with the multi-ID ramper he cannot substantiate any of false and misleading claims. Like all his posts not all the relevant information is being published on a UK website and only biased information is being disclosed on the website as its known that Med3000 is not a ‘regular&rsquo ˜some forms of bias, such as publication bias, should be considered as fraud’ petroc - 23 Feb 2023 - 21:53:12 - 16545 of 16566 Bias and Fraud There are numerous biases in medical research that render evidence from such research systematically misleading. Some of these biases are exacerbated by conflicts of interest, including fantastic financial incentives. The most important biases in medical research include confirmation bias, design bias, analysis bias, and publication bias. Arguably, some forms of bias, such as publication bias, should be considered as fraud. The pervasiveness of bias in medical research justifies one of the premises of the master argument for medical nihilism. Medical research is malleable due to the many biases, and such malleability allows for the production of evidence that suggests medical interventions are effective, whether or not they are in fact effective. | lbo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions